Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Pfizer

Related PFE
Fast Money Picks For August 28
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
Treasury Develolping Options to Curb Inversions (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “The 5% revenue miss in Q3'12 was forgiven to a degree as Lipitor phasing was partly to blame and EPS was still delivered through financial engineering. Lighter than expected Prevnar-13 and Enbrel sales were more concerning, though we now have the US launches of tofacitinib and hopefully Eliquis within the next 3-6 months to look forward to. New product launches, share repurchases and restructuring drive near term upside in our view.”

Pfizer closed on Friday at $24.16.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters